http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745188-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_714c0867ae91b2ff8abda4b2bc6e5e5f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-409 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3dc732fb81191c97fcfda658c598b33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e81da35efaf8fc3a6a23876976ff5daa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db93eafe12c7cbb175c3d60b96437463 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a5c5197b554800486ceaaa379bb8310 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_643f6cd6e9ca5300998cfeb7c5a9a3de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e629a783cd00ad5497b4e4df983f174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9775f4879e6fd4935eb418f5ec9b09eb |
| publicationDate | 2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2745188-C1 |
| titleOfInvention | Method for the treatment of non-segmental vitiligo with concomitant acne diagnosis |
| abstract | FIELD: dermatology.SUBSTANCE: invention can be used to treat patients with non-segmental vitiligo with a concomitant diagnosis of acne. To do this, a photosensitizer is applied to the lesions of the skin, followed by lesions exposure to the narrow-band ultraviolet radiation with a wavelength of 311 nm 2-3 times a week in the amount of 20 procedures. At the same time, prior to treatment of vitiligo, pretreatment of acne with tablets of amoxicillin + clavulanic acid at a dosage of 875 mg + 125 mg, lasting 10 days in combination with oral administration of isotretinoin 0.25-0.5 mg/kg of body weight is carried out.EFFECT: method makes it possible to increase the therapeutic efficacy of vitiligo treatment and avoid the risk of recurrent course of vitiligo while shortening the treatment time for vitiligo patients by several months by eliminating the trigger factor, namely, pretreatment of acne.1 cl, 2 ex |
| priorityDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.